Clinical Real-World Data Pilot Program: Fast-Track Entry Pathway into China

It usually takes at least three to five years for innovative new medical products to enter the Chinese market. However, procedure could be much shorter with the application supported by clinical RWD.
by Grace Wang Apr 12, 2021

China National Medical Products Administration (NMPA) recently granted conditional approval for Blueprint Medicines Corporation's GAVRETO (pralsetinib) through the priority review and approval procedure. 

Grace Wang
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact